Avelos Therapeutics
PrivateLast Round
Series B
Apr 30, 2024
Total Funding Raised
$20.3M
Momentum Score
25 /100
Company Overview
Avelos Therapeutics, Inc. is a South Korean biotechnology company founded in 2021 that specializes in the research and development of anti-cancer drugs. The company focuses on developing biomarker-driven, small molecule targeted therapies for what are considered "undruggable" cancer targets. Its core research areas include synthetic lethality, DNA damage response (DDR), and cell cycle regulation. Avelos Therapeutics' lead preclinical candidate is AD1208, a first-in-class MASTL kinase inhibitor. The company has raised approximately $21.7 million USD through seed, Series A, and Series B funding rounds, with the most recent Series B completed in April 2024. Avelos plans to pursue global technology transfers and an eventual listing on the KOSDAQ stock market.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avelos Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Avelos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 30, 2024 | ||||
| Series A | Aug 22, 2022 |
Key People
Founding team and executive leadership
Avelos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Investment | Series A, Series B |
| UTC Investment | Series A |
| QUAD Investment Management | Series A, Series B |
| STASSETS INVESTMENT | Series B |
| Heungkuk Securities | Series B |
| Medytox Venture Investment | Series B |
| LSK Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
Monthly visitors increased 114% MoM, reaching 2.7K.
Avelos Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Avelos Therapeutics's valuation, stock price, and market status.
